Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia
Open Access
- 4 November 2021
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 138 (18) , 1733-1739
Abstract
Although clonal hematopoiesis (CH) can precede the development of acute myeloid leukemia (AML), it can also persist after achieving remission. Long-term clonal dynamics and clinical implications of persistent CH are not well understood. Here, we studied the prevalence, dynamics, and clinical implications of postremission CH in 164 AML patients who attained complete remission after induction chemotherapies. Postremission CH was identified in 79 (48%) patients. Postremission CH persisted long term in 91% of the trackable patients despite treatment with various types of consolidation and maintenance therapies. Postremission CH was eradicated in 20 out of 21 (95%) patients who underwent allogeneic stem cell transplant. Although patients with postremission CH as a group had comparable hematopoiesis with those without it, patients with persistent TET2 mutations showed significant neutropenia long term. Postremission CH had little impact on relapse risk, nonrelapse mortality, and incidence of atherosclerotic cardiovascular disease, although the clinical impact of post-CR CH was heterogeneous among different mutations. These data suggest that although residual clonal hematopoietic stem cells are generally resistant to consolidation and maintenance therapies, they retain the ability to maintain normal hematopoiesis and have little impact on clinical outcomes. Larger study is needed to dissect the gene-specific heterogeneity.Keywords
This publication has 10 references indexed in Scilit:
- Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AMLBlood Advances, 2019
- Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2018
- Molecular Minimal Residual Disease in Acute Myeloid LeukemiaNew England Journal of Medicine, 2018
- Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesisLeukemia, 2018
- DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodelingNature Medicine, 2016
- Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AMLBlood, 2016
- Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid LeukemiaJAMA, 2015
- Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromesBlood, 2015
- Mutational Cooperativity Linked to Combinatorial Epigenetic Gain of Function in Acute Myeloid LeukemiaCancer Cell, 2015
- Age-Related Clonal Hematopoiesis Associated with Adverse OutcomesNew England Journal of Medicine, 2014